Neuroprotective effect of the novel glutamate AMPA receptor antagonist YM872 assessed with in vivo MR imaging of rat MCA occlusion

Brain Research

Volumn 811, Issue 1-2, 1998, Pages 63-70

  Håberg, Asta ^a   Takahashi, Masayasu ^b   Yamaguchi, Tokio ^b   Hjelstuen, Mari ^c   Haraldseth, Olav ^a,c  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b National Institute of Advanced Industrial Science and Technology   (Japan)

^c SINTEF   (Norway)

Author keywords

AMPA; Cerebral ischemia; Experimental stroke; MR imaging; Neuroprotective

Indexed keywords

[1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN SIZE; CONTINUOUS INFUSION; CONTROLLED STUDY; HISTOPATHOLOGY; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT;

ANIMALS; ARTERIAL OCCLUSIVE DISEASES; CEREBRAL ARTERIAL DISEASES; DRUG EVALUATION, PRECLINICAL; IMIDAZOLES; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; NEUROPROTECTIVE AGENTS; QUINOXALINES; RATS; RATS, WISTAR; RECEPTORS, AMPA;

EID: 0344197611     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)00957-3     Document Type: Article

References (40)

1. Bertrand G., Gross R., Puech R., Loubatières-Mariani M.M., Bockaert J. Evidence for a glutamate receptor of the AMPA subtype which mediates insulin release from rat perfused pancreas. Br. J. Pharmacol. 106:1992;354-359.
2. Buchan A.M., Lesiuk H., Barnes K.A., Hui L., Huang Z.-G., Smith K.E., Xue D. AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists? Stroke. 24:1993;I148-I152.
3. Bullock R., Graham D.I., Swanson S., McCulloch J. Neuroprotective effect of the AMPA receptor antagonist LY-293558 in focal cerebral ischemia in the cat. J. Cereb. Blood Flow Metab. 14:1994;466-471.
4. de Crespigny A.J., Tsuura M., Moseley M.E., Kucharczyk J. Perfusion and diffusion MR imaging of thromboembolic stroke. J.M.R.I. 3:1993;746-754.
5. Gill R., Nordholm L., Lodge D. The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) in a rat focal ischaemia model. Brain. Res. 580:1992;35-43.
6. Gill R. The pharmacology of α-amino-3-hydroxy-5-methyl-4-isoxasole propionate (AMPA)/kainate antagonists and their role in cerebral ischemia. Cerebrovasc. Brain Metab. Rev. 6:1994;225-256.
7. Gill R., Sibson N.R., Hatfield R.H., Burdett N.G., Carpenter T.A., Hall L.D., Pickard J.D. A comparison of the early development of ischaemic damage following permanent middle cerebral artery occlusion in rats as assessed using magnetic resonance imaging and histology. J. Cereb. Blood Flow Metab. 15:1995;1-11.
8. Graham S.H., Chen J., Lan J.Q., Simon R.P. A dose-response study of neuroprotection using the AMPA antagonist NBQX in rat focal cerebral ischemia. J. Pharmacol. Exp. Ther. 276:1996;1-4.
9. Hasegawa Y., Fisher M., Latour L.L., Dardzinski B.J., Sotak C.H. MRI diffusion mapping of reversible ischemic injury in focal brain ischemia. Neurology. 44:1994;1484-1490.
10. Hossmann K.-A. The pathophysiology of experimental brain edema. Neurosurg. Rev. 12:1989;263-280.
11. Jiang Q., Chopp M., Zhang Z.G., Helpern J.A., Ordidge R.J., Ewing J., Jiang P., Marchese B.A. The effect of hypothermia on transient focal ischemia in rat brain evaluated by diffusion- and perfusion-weighted NMR imaging. J. Cereb. Blood Flow Metab. 14:1994;732-741.
12. Kawasaki-Yatsugi S., Yatsugi S., Takahashi M., Toya T., Ichiki C., Shimizu-Sasamata M., Yamaguchi T., Minematsu K. A novel AMPA receptor antagonist, YM872, reduces infarct size after middle cerebral artery occlusion in rats. Brain Res. 793:1998;39-46.
13. Kiyota Y., Pahlmark K., Memezawa H., Smith M.-L., Siesjö B.K. Free radicals and brain damage due to transient middle cerebral artery occlusion: the effect of dimethylthiourea. Exp. Brain Res. 587:1993;66-72.
14. Knight R.A., Ordidge R.J., Helpern J.A., Chopp M., Rodolosi L.C., Peck D. Temporal evolution of ischemic damage in rat brain measured by proton nuclear magnetic resonance imaging. Stroke. 22:1991;802-808.
15. Koek W., Woods J.H., Winger G.D. MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioural effects in pigeons, rats and rhesus monkeys. J. Pharmacol. Exp. Ther. 245:1988;969-974.
16. A. Kohara, M. Okada, R. Tsutsumi, K. Ohno, M. Takahashi, M. Shimizu-Sasamata, J. Shishikura, H. Inami, S. Sakamoto, T. Yamaguchi, In vitro characterization of YM872: a selective, potent and highly water-soluble α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptor antagonist, J. Pharm. Pharmacol., 1998, in press.
17. Kohno K., Höhn-Berlage M., Mies G., Back T., Hossmann K.-A. Relationship between diffusion-weighted MR images, cerebral blood flow, and energy state in experimental brain infarction. Magn. Reson. Imag. 13:1995;73-80.
18. Liu H.-P., Tay S.S.-W., Leong S.-K. Localization of glutamate receptor subunits of the α-amino-3-hydroxy-5-methyl-4-isoxasoleproprionate (AMPA) type in the pancreas of newborn guinea pigs. Pancreas. 14:1997;360-368.
19. Lo E.H., Pierce A.R., Mandeville J.B., Rosen B.R. Neuroprotection with NBQX in rat focal cerebral ischemia. Effects on ADC probability distribution functions and diffusion-perfusion relationship. Stroke. 28:1997;439-447.
20. Memezawa H., Minamisawa H., Smith M.-L., Siesjö B.K. Ischemic penumbra in a model of reversible middle cerebral artery occlusion in the rat. Exp. Brain. Res. 89:1992;67-78.
21. Minematsu K., Fisher M., Li L., Davis M.A., Knapp A.G., Cotter R.E., McBurney R.N., Sotak C.H. Effects of a novel NMDA antagonist on experimental stroke rapidly and quantitatively assessed by diffusion-weighted MRI. Neurology. 43:1993;397-403.
22. Mintorovitch J., Moseley M.E., Chileuitt L., Shimizu H., Cohen Y., Weinstein P.R. Comparison of diffusion- and T2-weighted MRI for the early detection of cerebral ischemia and reperfusion in rats. Magn. Reson. Med. 18:1991;39-50.
23. Morris R.G.M., Anderson E., Lynch G.S., Baudry M. Selective impairment of learning and blockade of long-term potentiation by N-methyl-D-aspartate receptor antagonist, AP5. Nature. 319:1986;774-776.
24. Müller T.B., Haraldseth O., Jones R.A., Sebastiani G., Godtliebsen F., Lindboe C.F., Unsgård G. Combined perfusion and diffusion-weighted magnetic resonance imaging in a rat model of reversible middle cerebral artery occlusion. Stroke. 26:1995;451-458.
25. Müller T.B., Haraldseth O., Jones R.A., Sebastiani G., Lindboe C.F., Unsgård G., Øksendal A.N. Perfusion and diffusion weighted MR imaging for in vivo evaluation of treatment with U73489G in a rat stroke model. Stroke. 26:1995;1453-1458.
26. Nagasawa N., Kogure K. Correlation between cerebral blood flow and histological changes in a new rat model of middle cerebral artery occlusion. Stroke. 20:1989;1037-1043.
27. Nurse S., Corbett D. Neuroprotection after several days of mild drug-induced hypothermia. J. Cereb. Blood Flow Metab. 16:1996;474-480.
28. Olney J.W., Labruyere J., Price M.T. Pathological changes induced in cerebrocortical neurones by phencyclidine and related drugs. Science. 244:1989;1360-1362.
29. Olney J.W., Labruyere J., Wang G., Wosniak D.F., Price M.T., Sesma M.A. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 254:1991;1515-1518.
30. G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, 2nd edn., Academic Press, San Diego, 1986, ISBN 0-12-547621-3.
31. Roussel S.A., van Bruggen N., King M.D., Houseman J., Williams S.R., Gadian D.G. Monitoring the initial expansion of focal ischaemic changes by diffusion-weighted MRI using remote controlled method of occlusion. NMR in Biomed. 7:1994;21-28.
32. Smith S.E., Meldrum B.S. Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, GYKI 52466, after focal ischemia in the rat. Stroke. 23:1992;861-864.
33. Takahashi M., Ni J.W., Kawasaki-Yatsugi S., Toya T., Yatsugi S., Shimizu-Sasamata M., Koshiya K., Shishikura J., Sakamoto S., Yamaguchi T. YM872, a novel selective α-amino-3-hydroxy-5 methylisoxazole-4-propionic acid receptor antagonist reduces brain damage after permanent focal cerebral ischemia in cats. J. Pharmacol. Exp. Ther. 284:1998;467-473.
34. M. Takahashi, J.W. Ni, S. Kawasaki-Yatsugi, T. Toya, C. Ichiki, S. Yatsugi, K. Koshiya, M. Shimizu-Sasamata, T. Yamaguchi, Neuroprotective efficacy of YM872, an α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, after permanent middle cerebral artery occlusion in rats, J. Pharmacol. Exp. Ther., in press.
35. Verheul H.B., Berkelbach van der Sprenkel J.W., Tulleken C.A., Tamminga K.S., Nicolay K. Temporal evolution of focal cerebral ischemia in the rat assessed by T2-weighted and diffusion-weighted magnetic resonance imaging. Brain Topogr. 5:1992;171-176.
36. Weaver C.D., Yao T.L., Powers A.C., Verdoorn T.A. Differential expression of glutamate receptor subtypes in rat pancreatic islets. J. Biol. Chem. 271:1996;12977-12984.
37. Xue D., Huang Z.-G., Barnes K., Lesiuk H.J., Smith K.E., Buchan A.M. Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction. J. Cereb. Blood Flow Metab. 14:1994;251-261.
38. Yao H., Ibayashi S., Nakane H., Cai H., Uchimura H., Fujishima M. AMPA receptor antagonist, YM90K, reduces infarct volume in thrombotic distal middle cerebral artery occlusion in spontaneously hypertensive rats. Brain Res. 753:1997;80-85.
39. Yatsugi S., Takahashi M., Kawasaki-Yatsugi S., Koshiya K., Sakamoto S., Uematsu D., Shimizu-Sasamata M. Neuroprotective effect of YM90K, a novel AMPA/kainate receptor antagonist, in focal cerebral ischemia in cats. J. Cereb. Blood Flow Metab. 16:1996;959-966.
40. Zhao Q., Memezawa H., Smith M.-L., Siesjö B.K. Hyperthermia complicates middle cerebral artery occlusion induced by an intraluminal filament. Brain Res. 649:1994;253-259.